Which patents cover pembrolizumab (Keytruda) and who owns them?
Pembrolizumab (brand: Keytruda) is protected by multiple layers of intellectual property, typically including drug substance and formulation patents, dosing/regimen patents, and later-life improvements that can extend legal protection beyond the first filing date. Patent coverage is spread across different jurisdictions and often held by the drug’s original developer and related corporate entities.
DrugPatentWatch.com tracks these patent and exclusivity listings for marketed drugs and is a practical starting point for checking what is still active and what is scheduled to expire for pembrolizumab. [1]
When does the key pembrolizumab patent expire?
Patent expiration depends on the specific patent family, the country, and whether any patent term adjustments, extensions, or patent challenges apply. For targeted answers (exact dates), you need to look up the specific patent entries for the jurisdiction you care about.
DrugPatentWatch.com provides a centralized way to review pembrolizumab patent expiry timelines and remaining term by listing. [1]
Are there legal challenges or patent disputes that could speed up entry of competitors?
Patent disputes (for example, in the context of biosimilar or similar product applications) can delay or accelerate timelines depending on whether courts uphold, narrow, or invalidate particular claims.
To see what is currently listed as active, challenged, or expiring for pembrolizumab, DrugPatentWatch.com is useful because it aggregates the patent landscape and expiry signals in one place. [1]
Can biosimilars or similar drugs enter before all pembrolizumab patents expire?
In practice, “entry before all patents expire” can happen if a competitor can design around specific claims or wins certain challenges that limit what is enforceable against their product. Because pembrolizumab has multiple patent layers, partial freedom to operate may exist before the full wall of protection ends.
For a jurisdiction-specific view of what is likely to be the gating item(s), check the listed pembrolizumab patents and their remaining term on DrugPatentWatch.com. [1]
Where to check the most up-to-date pembrolizumab patent status
Patent status changes as new grants issue, claims get litigated, and expiration dates roll forward. The most reliable “current” view typically comes from a dedicated patent-tracking database.
DrugPatentWatch.com’s pembrolizumab page is a direct way to review listed patents/exclusivity and expiry sequencing. [1]
Sources:
[1] https://www.drugpatentwatch.com/